 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more...

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares

HC Wainwright restated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX Free Report) in a research note released on Wednesday, Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright also issued estimates for Unity Biotechnologys Q3 2023 earnings at ($1....

Unity Biotechnology (NASDAQ:UBX) Stock Rating Reaffirmed by HC Wainwright

Unity Biotechnology, Inc. (NASDAQ:UBX  Free Report)  Research analysts at HC Wainwright raised their Q3 2023 earnings estimates for shares of Unity Biotechnology in a research report...

Equities Analysts Set Expectations for Unity Biotechnology, Inc.'s Q3 2023 Earnings (NASDAQ:UBX)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX Research Report), with a pr... In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX &#8211...

H.C. Wainwright Keeps Their Buy Rating on Unity Biotechnology (UBX)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology (UBX Research Report) today and set a price target of $6.00. ... Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology (UBX  Research Re...

Unity Biotechnology (UBX) Receives a Buy from Mizuho Securities

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. We are focused on ...

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

Unity Biotechnology, Inc. (NASDAQ:UBX Free Report) Research analysts at Cantor Fitzgerald issued their FY2023 earnings estimates for Unity Biotechnology in a note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings per share of ($3....

Brokers Set Expectations for Unity Biotechnology, Inc.'s FY2023 Earnings (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX  Free Report)  Cantor Fitzgerald issued their FY2023 EPS estimates for shares of Unity Biotechnology in a research report issued to clients and investors on Tuesday, July 11th. Cantor Fitzgerald analyst J. Kim anticipates that the company will post...

Brokers Issue Forecasts for Unity Biotechnology, Inc.'s FY2023 Earnings (NASDAQ:UBX)

Wedbush lowered shares of Unity Biotechnology (NASDAQ:UBX Free Report) from an outperform rating to a neutral rating in a research note published on Monday, The Fly reports. Several other analysts have also recently issued reports on the company. Mizuho dropped their target price on Unity ...

Unity Biotechnology (NASDAQ:UBX) Cut to Neutral at Wedbush

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Watchers	3,917
52-Wk Low	$1.46
52-Wk High	$5.72

Market Cap	$35.19M
Volume (M)	247.00
52-Wk High	$5.72
52-Wk Low	$1.46

UBX Unity Biotechnology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals